Abstract
Background: Clomiphene is normally used in women with ovulatory dysfunction. In men, it is used off label in some cases of infertility. Psychological adverse effects are reported in women but very few in men.
Case: A 34-year-old man treated with clomiphene for oligoteratospermia presented anxiety, decreased appetite, and mood change making him unable to function properly at work, five days after initiation of therapy. Symptoms required reduction followed by discontinuation of treatment four days later because of absence of improvement. Following cessation, the patient noted a gradual then a complete resolution approximately one week later. The patient did not have any psychiatric or other medical condition neither drug nor substance abuse that could explain this clinical presentation. The Naranjo's score was used to prove the clomiphene's imputability.
Conclusion: Health care providers should advise patients of the risk of psychological adverse effects when initiating treatment with clomiphene and should provide a close monitoring of mood change, especially during the initial weeks.
Keywords: Anxiety, clomiphene, drug-related side effects and adverse reactions, infertility, male, mood disorders.
Current Drug Safety
Title:Clomiphene for the Treatment of Male Infertility: A Case Report of Mood Change and a Literature Overview
Volume: 12 Issue: 3
Author(s): Marine Aussedat, Jennifer Jean-Louis, Orchidee Djahangirian and Marie-Sophie Brochet*
Affiliation:
- CHU Sainte-Justine, 3175 Chemin de la Cote-Sainte-Catherine, Montreal (Quebec) H3T 1C5,Canada
Keywords: Anxiety, clomiphene, drug-related side effects and adverse reactions, infertility, male, mood disorders.
Abstract: Background: Clomiphene is normally used in women with ovulatory dysfunction. In men, it is used off label in some cases of infertility. Psychological adverse effects are reported in women but very few in men.
Case: A 34-year-old man treated with clomiphene for oligoteratospermia presented anxiety, decreased appetite, and mood change making him unable to function properly at work, five days after initiation of therapy. Symptoms required reduction followed by discontinuation of treatment four days later because of absence of improvement. Following cessation, the patient noted a gradual then a complete resolution approximately one week later. The patient did not have any psychiatric or other medical condition neither drug nor substance abuse that could explain this clinical presentation. The Naranjo's score was used to prove the clomiphene's imputability.
Conclusion: Health care providers should advise patients of the risk of psychological adverse effects when initiating treatment with clomiphene and should provide a close monitoring of mood change, especially during the initial weeks.
Export Options
About this article
Cite this article as:
Aussedat Marine, Jean-Louis Jennifer, Djahangirian Orchidee and Brochet Marie-Sophie *, Clomiphene for the Treatment of Male Infertility: A Case Report of Mood Change and a Literature Overview, Current Drug Safety 2017; 12 (3) . https://dx.doi.org/10.2174/1574886312666170616092036
DOI https://dx.doi.org/10.2174/1574886312666170616092036 |
Print ISSN 1574-8863 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3911 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
BRCA1 as Target for Breast Cancer Prevention and Therapy
Anti-Cancer Agents in Medicinal Chemistry DNA Methylation in Epithelial Ovarian Cancer: Current Data and Future Perspectives
Current Molecular Pharmacology Anti-inflammatory Phytochemicals for Chemoprevention of Colon Cancer
Current Cancer Drug Targets HDAC Inhibitors as Novel Anti-Cancer Therapeutics
Recent Patents on Anti-Cancer Drug Discovery Cellular Senescence in the Development and Treatment of Cancer
Current Pharmaceutical Design The Targets of Curcumin
Current Drug Targets PI3K/Akt/JNK/c-Jun Signaling Pathway is a Mediator for Arsenite- Induced Cyclin D1 Expression and Cell Growth in Human Bronchial Epithelial Cells
Current Cancer Drug Targets Induction of Senescent-Like Growth Arrest as a New Target in Anticancer Treatment
Current Cancer Drug Targets The Immunomodulatory Potential of Selected Bioactive Plant-Based Compounds in Breast Cancer: A Review
Anti-Cancer Agents in Medicinal Chemistry Effect of Salinomycin on Expression Pattern of Genes Associated with Apoptosis in Endometrial Cancer Cell Line
Current Pharmaceutical Biotechnology FER1L4: A Long Non-coding RNA with Multiple Roles in the Occurrence and Development of Tumors
Current Pharmaceutical Design Estrogen, Immunity & Autoimmune Disease
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Diabetes, Cancer and Treatment – A Mini-Review
Current Drug Safety Reproductive Toxicology of Environmental Toxicants: Emerging Issues and Concerns
Current Pharmaceutical Design Is Metformin a Therapeutic Paradigm for Colorectal Cancer: Insight into the Molecular Pathway?
Current Drug Targets Rapid Non-genomic Vasodilator Actions of Oestrogens and Sex Steroids
Current Medicinal Chemistry Targetin g Human Tel omerase by Antisens e Oligonucleotides and Ribozymes
Current Medicinal Chemistry - Anti-Cancer Agents Folate-Linked Lipid-Based Nanoparticle for Targeted Gene Delivery
Current Drug Delivery The Role of Glycogen Synthase Kinase-3β in Normal Haematopoiesis, Angiogenesis and Leukaemia
Current Medicinal Chemistry Manipulation of Glycolysis in Malignant Tumors: Fantasy or Therapy?
Current Medicinal Chemistry